Chemistry:Amonafide

From HandWiki
Short description: Chemical compound
Amonafide
Amonafide.svg
Clinical data
Trade namesXanafide, Quinamed
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC16H17N3O3
Molar mass299.330 g·mol−1
3D model (JSmol)
  (verify)

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.[1][2]

It was being developed as an anti-cancer therapy by Antisoma.[3]

(As of 2008), it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).[4] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.[citation needed]

See also

References

  1. "Amonafide: a potential role in treating acute myeloid leukemia". Expert Opinion on Investigational Drugs 20 (7): 995–1003. July 2011. doi:10.1517/13543784.2011.585756. PMID 21591994. 
  2. "Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?". Expert Review of Hematology 5 (1): 17–26. February 2012. doi:10.1586/ehm.11.68. PMID 22272701. 
  3. "Antisoma's Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial". Genetic Engineering & Biotechnology News. 29 March 2010. http://www.genengnews.com/news/bnitem.aspx?name=78979622. 
  4. Clinical trial number NCT00715637 for "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study" at ClinicalTrials.gov

External links

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".